Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: mepolizumab, GlaxoSmithKline.

Gnanasegaram Gnanakumaran1, K Suresh Babu

  • 1Mail Point 810, Level D, Centre Block, Southampton General Hospital, Southampton, SO16 6YD, UK.

Current Opinion in Molecular Therapeutics
|July 23, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis, optical and raman spectra of cobalt ditellurite, CoTe<sub>2</sub>O<sub>5</sub> single crystal.

Scientific reports·2026
Same author

Memristive nano-neuromorphic spiking neural network with self-adaptive continual and predictive learning for edge gesture recognition.

Scientific reports·2026
Same author

Comment on "impact of percutaneous endoscopic gastrostomy (PEG) timing on mortality in intensive care unit patients: The modifying role of the prognostic nutritional index (PNI)".

Clinical nutrition ESPEN·2026
Same author

Comment on "Comparison of postoperative infection risk with and without topical vancomycin in adult posterior spinal fusion: a propensity-matched cohort study of 126,910 patients".

Spine deformity·2026
Same author

Comment on "Preoperative thoracic epidural analgesia with and without erector spinae plane block for thoracotomy: A retrospective study".

Journal of the Formosan Medical Association = Taiwan yi zhi·2026
Same author

Comment on "Long-term surgical outcomes of hemiarthroplasty for patients with femoral neck fracture with metal versus ceramic head in Taiwan".

Journal of the Formosan Medical Association = Taiwan yi zhi·2026

GlaxoSmithKline is developing mepolizumab, an antibody targeting IL-5, for asthma and atopic dermatitis. Phase II clinical trials for both conditions were initiated by 2002.

Area of Science:

  • Immunology and Pharmacology
  • Development of targeted biologic therapies

Background:

  • Interleukin-5 (IL-5) is a key cytokine implicated in eosinophilic inflammation.
  • Asthma and atopic dermatitis are chronic inflammatory conditions often associated with elevated IL-5 levels.
  • Targeting IL-5 offers a potential therapeutic strategy for these allergic diseases.

Purpose of the Study:

  • To evaluate the efficacy and safety of mepolizumab, a monoclonal antibody against IL-5.
  • To investigate mepolizumab as a treatment for patients with asthma.
  • To assess mepolizumab's potential in managing atopic dermatitis.

Main Methods:

  • Development of mepolizumab (SB-240563), a humanized monoclonal antibody.
  • Conducting Phase II clinical trials to assess therapeutic potential.

Related Experiment Videos

  • Focus on patient populations with asthma and atopic dermatitis.

    • Main Results:

    • Phase II trials for asthma were initiated by April 1998.
    • Phase II trials for atopic dermatitis commenced by March 2002.
    • Ongoing evaluation of clinical outcomes and safety profiles in target patient groups.

    Conclusions:

    • Mepolizumab represents a targeted approach for managing IL-5-driven inflammation.
    • Clinical development is progressing through Phase II trials for asthma and atopic dermatitis.
    • Further research will determine the therapeutic role of mepolizumab in allergic diseases.